Momenta Pharmaceuticals, Inc. (MNTA) President Craig A. Wheeler Sells 35,667 Shares
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) President Craig A. Wheeler sold 35,667 shares of the firm’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $19.03, for a total transaction of $678,743.01. Following the transaction, the president now owns 286,121 shares of the company’s stock, valued at approximately $5,444,882.63. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Craig A. Wheeler also recently made the following trade(s):
- On Friday, September 1st, Craig A. Wheeler sold 20,367 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $17.00, for a total transaction of $346,239.00.
- On Thursday, August 10th, Craig A. Wheeler sold 16,953 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $16.94, for a total transaction of $287,183.82.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) opened at 17.95 on Tuesday. Momenta Pharmaceuticals, Inc. has a 1-year low of $10.75 and a 1-year high of $19.90. The firm has a 50-day moving average of $16.82 and a 200 day moving average of $15.79. The firm’s market cap is $1.33 billion.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The company had revenue of $23.57 million for the quarter, compared to analyst estimates of $24.64 million. During the same quarter last year, the firm posted ($0.31) earnings per share. Momenta Pharmaceuticals’s revenue was down 10.8% compared to the same quarter last year. Analysts expect that Momenta Pharmaceuticals, Inc. will post ($1.39) earnings per share for the current fiscal year.
WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) President Craig A. Wheeler Sells 35,667 Shares” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/10/03/momenta-pharmaceuticals-inc-mnta-president-craig-a-wheeler-sells-35667-shares.html.
A number of brokerages recently weighed in on MNTA. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Momenta Pharmaceuticals in a report on Thursday, September 28th. They set a “neutral” rating and a $18.00 target price for the company. Stifel Nicolaus reissued a “buy” rating and set a $26.00 price objective on shares of Momenta Pharmaceuticals in a research note on Thursday, August 3rd. BidaskClub cut Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, July 6th. Zacks Investment Research lowered Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, Maxim Group set a $6.00 target price on Momenta Pharmaceuticals and gave the company a “sell” rating in a report on Thursday, August 3rd. Three analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $16.78.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Edmond DE Rothschild Holding S.A. acquired a new stake in Momenta Pharmaceuticals during the 1st quarter worth approximately $5,607,000. Great West Life Assurance Co. Can lifted its stake in Momenta Pharmaceuticals by 8.4% in the second quarter. Great West Life Assurance Co. Can now owns 96,471 shares of the biotechnology company’s stock valued at $1,625,000 after buying an additional 7,450 shares in the last quarter. Rhumbline Advisers lifted its stake in Momenta Pharmaceuticals by 8.6% in the second quarter. Rhumbline Advisers now owns 140,215 shares of the biotechnology company’s stock valued at $2,370,000 after buying an additional 11,128 shares in the last quarter. Comerica Bank lifted its stake in Momenta Pharmaceuticals by 5.4% in the first quarter. Comerica Bank now owns 71,875 shares of the biotechnology company’s stock valued at $1,006,000 after buying an additional 3,652 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Momenta Pharmaceuticals by 65.1% in the first quarter. JPMorgan Chase & Co. now owns 636,744 shares of the biotechnology company’s stock valued at $8,500,000 after buying an additional 251,159 shares during the period. 93.86% of the stock is owned by institutional investors and hedge funds.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.